Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group.
about
Adenosine versus intravenous calcium channel antagonists for the treatment of supraventricular tachycardia in adultsAdenosine versus intravenous calcium channel antagonists for the treatment of supraventricular tachycardia in adultsAudit of therapeutic interventions in inpatient children using two scores: are they evidence-based in developing countries?Meta-analysis of the Risk of Torsades de Pointes in patients treated with intravenous racemic sotalol.Haemodynamic deterioration after treatment with adenosine.Comparative transcriptome analysis of Bacillus subtilis responding to dissolved oxygen in adenosine fermentationCurrent trends in supraventricular tachycardia management.A comparison of an A1 adenosine receptor agonist (CVT-510) with diltiazem for slowing of AV nodal conduction in guinea-pig.To decide medical therapy according to ECG criteria in patients with supraventricular tachycardia in emergency department: adenosine or diltiazem.A model for priority setting of health technology assessment: the experience of AHP-TOPSIS combination approachIntravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients.Pharmacotherapy considerations in advanced cardiac life support.Prehospital use of adenosine by ambulance services in the Netherlands: Daily practice, literature overview and practical recommendations.Review article: Adenosine use in the emergency department.Supraventricular tachycardia. Changes in management.Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias: Endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulacióAdenosine induced ventricular fibrillation in a structurally normal heart: a case report.Should radiofrequency therapy be performed in every symptomatic patient with supraventricular tachycardia? (Pro drug position).Supraventricular Arrhythmias in Patients with Adult Congenital Heart DiseaseTerminating paroxysmal supraventricular tachycardias with adenosine.Myocardial infarction related atrial fibrillation: role of endogenous adenosine.Pharmacokinetics and tolerability of intravenous infusion of adenosine (SUNY4001) in healthy volunteers.Imaging of adenosine bolus transit following intravenous administration: insights into antiarrhythmic efficacy.Acceleration of ventricular response to atrial flutter after intravenous adenosine.Adenosine and cardiac arrhythmias.Adenosine-induced tachycardia acceleration: an unusual proarrhythmia.Recent caffeine ingestion reduces adenosine efficacy in the treatment of paroxysmal supraventricular tachycardia.Electrophysiologic characteristics of wide QRS complexes during pharmacologic termination of sustained supraventricular tachycardias with verapamil and adenosine: observations from electrophysiologic study.Noninvasive diagnosis of cardiac arrhythmias using adenosine compounds.Dexmedetomidine: therapeutic use for the termination of reentrant supraventricular tachycardia.Adenosine-induced ventricular arrhythmias in patients with supraventricular tachycardias.Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia.European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca yAn unusual complication of adenosine administration in supraventricular tachycardia.Adenosine A2A Receptor Antagonists in Neurodegenerative Diseases: Huge Potential and Huge Challenges.
P2860
Q24203743-3CC3AA3F-6203-413C-B47F-EE3EC020B30DQ24243895-C11F3B26-2D57-4E0B-84AA-8B443E9A0905Q24800327-F97B1B5E-6BAA-4C57-B7D7-6950184BC1ABQ31827349-636B4609-0B61-42FD-A962-799F0831811FQ33613893-498A20D1-18A0-4B96-A348-C8EC90F556C2Q33916761-2CDDC903-76E7-4BD7-9006-11CA13DE1955Q34971701-15BB68F4-F80C-4044-A23C-8F49EE187A52Q35028359-3A6EE828-F4DE-4D11-A561-EBC4732E2460Q35958684-49619FCB-F3E8-4C92-B101-52CE3B351604Q35986702-E7EFD49E-05FB-4AD3-BB79-2A2978FF44B8Q36087660-DE9D4584-FDAB-4E33-9B8B-59BEFAA438C2Q36662909-6EA4A5AB-C69D-4B3F-BB69-10469990B3E0Q36817537-B65D9858-E602-41A8-9A6D-ECE8557BAEF2Q37189743-4161AFF6-8B47-4F0A-8AEA-192ECCCB43A1Q37213818-BBBE9462-A8E0-412B-BA9A-8BC5FFCC1596Q37596058-4AC75F0B-8DC2-42B6-841A-52998805F611Q37597761-5EF3D6EC-A190-45BD-A702-2BC233B7C6A6Q40485964-2E5DDDDF-633E-41DE-9AD8-C8DEEBE523DAQ41061222-96AF724D-4CF7-4844-B9FD-0D6A03723E73Q41188752-ED9161A9-406C-4B44-9C8A-36E96A0F7539Q41344385-6F8690B3-1DDB-40F0-A371-CD9C7151B022Q41597075-4D2DB434-D234-4DA7-A5CA-A4178CEBBE20Q41868402-3E5FAE2F-2477-4C1F-83EE-1787483A37AAQ41990836-6794A6D3-2043-43C0-8345-060E53D04239Q42999326-14737C45-D1B9-47EF-892C-B1D0590FFFA2Q43140041-7CB73BC1-8F42-4905-96E6-4D5444344EB4Q43225220-1152433B-B85D-4B0F-B52A-198AF7F69AEAQ43266976-CDF6D2C2-08BF-4C2B-8FE4-F30B77C2A077Q43885923-D926C161-0551-49B3-A152-FE6612F67165Q44419734-05589EE3-149E-4BE0-A91E-65B8BCE5DFA8Q46273402-43A9C8FF-C117-436D-A849-CBD4B175137BQ47809864-CFBDDEEC-3DD7-4702-8D3C-AE90682658C3Q48032949-85611F4F-9B87-4E60-B08D-0CB7E79899B8Q49487300-74AC8B08-A160-4072-B126-8F800DCCB2DFQ55297865-088CBA49-DF0D-4559-A74E-7C9DF07F6CC9
P2860
Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group.
description
1990 nî lūn-bûn
@nan
1990 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Adenosine for paroxysmal supra ...... denosine for PSVT Study Group.
@ast
Adenosine for paroxysmal supra ...... denosine for PSVT Study Group.
@en
type
label
Adenosine for paroxysmal supra ...... denosine for PSVT Study Group.
@ast
Adenosine for paroxysmal supra ...... denosine for PSVT Study Group.
@en
prefLabel
Adenosine for paroxysmal supra ...... denosine for PSVT Study Group.
@ast
Adenosine for paroxysmal supra ...... denosine for PSVT Study Group.
@en
P2093
P921
P1476
Adenosine for paroxysmal supra ...... denosine for PSVT Study Group.
@en
P2093
DiMarco JP
McGovern B
Milstein S
Scheinman MM
P304
P356
10.7326/0003-4819-113-2-104
P407
P577
1990-07-01T00:00:00Z